

Appendix G

Declaration of Interests

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Mahmoud Barbir	None	None	None	None	None
Neill Calvert	(Non-current) I was sub-contracted by the University of Sheffield to undertake a review of the evidence for cost-effectiveness of third line treatments for breast cancer for Bristol Myers Squibb. This work was undertaken in July and August of 2007	None	None	None	None
Dawn Davies	None	Patient Trustee Director of Heart UK. (which receives 25% funding from the pharmaceutical industry). In past year have been asked to speak on television for The Money Programme on functional foods and on the role of patients and the media for London Ideas and received only travel expenses. Member of strategic planning committee on patient safety for University of Bristol Hospitals Trust	None	None	None

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Kathleen DeMott	None	None	None	None	None
Steve Humphries	None	None	A colleague in the Centre for Cardiovascular Genetics has a grant from GSK to use Mendelian Randomisation to explore causality for Lp-PLA2. Supervise a BBSC/Unilever PhD student to look at gene-nutrient interaction.	I am a member of the British Atherosclerosis Society which receives an educational grant from AstraZeneca to help run the meetings. I am the treasurer of the European Atherosclerosis Society which has a number of corporate members which include AstraZeneca, Fornia, KRKA, Novartis, PLIVA, Pfizer, MSD-Sheering, SanofiAventis. Each company pays a standard amount which is used for the general running of the society, to support students bursaries etc	I act as an unpaid consultant for the company Tepnel which is developing a testing kit for common mutations in patients with FH. I have a confidentiality disclosure agreement with a company Randox, who is developing a genetic testing kit for patients with coronary heart disease. Based on modelling, I have published papers stating that cascade testing to identify relatives of FH patients is cost effective. Based on data I have generated with others, I have published papers demonstrating the potential clinical utility of genetic testing in the identification and management of patients with FH. based on data collected in collaboration with others, I have published papers stating that DNA testing in the relatives of patients with FH is not associated with any significant psychological harm

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Meeta Kathoria	<p>I have received £900 from a healthcare communications agency, Strategic Consultants International, as a result of editing slides for a medical education slide set for a Pfizer pain product, as well as doing some broad market research on sleeping disorders for the agency.</p> <p>Both parents own shares in GlaxoSmithKline, these were purchased much before 2006 when I started at the RCGP</p>	None	None	None	None

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Philip Lee	None	Secretary of SSIEM Council Member of JCHMT sub-committee for Metabolic Medicine Responded to RCPCH questionnaire on NICE GDG membership	Non-personal specific pecuniary interest ISIS sponsored PI for trial of medication in homozygous familial hypercholesterolaemia (from May 2007 onwards)	Non-personal non-specific pecuniary interest Grant for Clinical Research Fellow to run starch trial in GSD Grant for Research Nurse to run Immunokine in AMN trial Grant for Research Dietitian to run never-treated PKU trial Grant for Research Dietitian to run nutritional studies PI of trial of phenoptin therapy in phenylketonuria	Member of European Fabry Disease Registry Board Member of Data Safety Monitoring Board for Fabrazyme trials Member of Zavesca Advisory Board
Anneke Lucassen	None	None	None	None	None

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Ian McDowell	None	Paid attendance at conference by MSD	<p>£30,0000 grant to fund a FH specialist nurse paid to Bro Morgannwg Trust-August 2005- July 2006-From MSD (not responsible for administering grant).</p> <p>July 2006 –Nov 2007 to part fund a FH specialist nurse Pfizer Approx 8K</p> <p>Feb 2007 –January 2008 Astra Zeneca 20K to part fund a FH specialist nurse</p> <p>Mar 2007 - Presented to a local group of 15 GPs at the GPs request on general aspects of Familial Hypercholesterolaemia. GPs had arranged that the meeting be sponsored (by Schering Plough Ltd) and involved transference of honorarium of £300 paid into a university research account.</p>	None	None
Rubin Minhas	Authorship fee for book publication 'ECGs for Healthcare Professionals'	2006 Advisory board, Renin Inhibitor	2006/07/08 SAHF (Office: Chair Cardiovascular Working Group – SAHF received unrestricted funding from Schering Plough/ Astrazeneca/MSD/Pfizer)	None	None

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Leo Nherera	None	None	None	None	None
Andrew Neil	<p>Personal specific pecuniary or personal family interest</p> <p>Member of Pfizer US Diabetes Advisory Board</p> <p>Member of MSD-Schering Plough Lipid Advisory Board</p> <p>Member of Solvay Health Care Cardiovascular Advisory Board</p>	None	<p>Financial support from Pfizer for the Atorvastatin in Factorial with omega-3 polyunsaturated fatty acids for cardiovascular risk reduction in patients with type Diabetes Trial (AFORRD).</p> <p>ProNovo Biocare: support for a sub-study of the AFORRD trial</p> <p>Merk Sharpe & Dohme: support for a sub-study of non-cholesterol sterols as part of the AFORRD trial</p>	<p>Access to non-linked anonymised data from a national cardiovascular screening programme</p> <p>of about 73,000 adults in Great Britain that was funded by Unilever. The protocol was designed by a Scientific Advisory Board of which I was a member.</p>	<p>Chairman of HEART UK which a DoH recognised specialist society and patient organisation that lobbies on behalf of patients with familial hypercholesterolaemia (it receives about 25% of funding from the pharmaceutical industry, about 50% from the food industry, government support and contributions from individuals)</p>
Vanessa Nunes	None	None	None	None	None
Aileen Parke	None	None	None	None	None
Nadeem Qureshi	None	<p>Member of group linking doctors to media activity (Media Medics)</p> <p>Member of Primary Care Genetics Group</p>	<p>Grants held from Department of Health to evaluate the clinical utility of the Coronary Heart Disease family history in primary care and for Applied Genetic R&D in Primary Care</p>	None	None
Gill Ritchie	None	None	None	None	None

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Philip Rowlands	None	Education consultant, Expert Patient, Writer Heart UK which receives 25% funding from the pharmaceutical industry)	None	None	None
Mary Seed	None	Honorary Chairman to the Preventive Cardiology Trust, a charity based at the Charing Cross Hospital, Department of Cardiology. This provides for registration and expenses for one scientific meeting attendance annually	None	Adhoc consulting -medical advice by phone email for McNeil	Honorary Secretary Scientific Steering Committee Simon Broome
Elizabeth Shaw	None	None	None	None	None
Helen Stracey	None	None	None	Department of Dietetics and Nutrition received a Training allowance for 12 months (department has approx 14 dietitians) from Abbott Laboratories	None
Margaret Thorogood	None	None	None	None	I am author of an HTA review and subsequent peer reviewed papers on FH
Meiyin Tok	None	None	None	None	None

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Anthony Wierzbicki	Consultancy agreement (fenofibrate) -Fournier-Solvay Lecture honoraria & advisory boards (nicotinic acid)-Merk Kga Advisory boards (ezetimibe and simvastatin-ezetimibe) - Merck Sharp & Dohme/Schering - Plough	None	None	Chairman, Medical, Scientific & Research Committee, HEART-UK (which receives 25% funding from the pharmaceutical industry)	None
Melanie Watson	None	Current Msc in Genetic Counselling (University of Cardiff)-Paid for by Astra Zeneca	None	None	None
Helen Williams	Received funding in last 12 months from: Pfizer: Oct 2006 Boston Scientific: Jan 2007 E Merck Ltd: Feb 2007 Sanofis Aventis: Oct 2007 Schering Plough: Oct 07 Solvay: Dec 07	None	None	Have participated in 'Working with the Industry' projects within Lambeth and Southwark PCTs and SEL Cardiac network which engages the following companies: Sanofi-Aventis, Takeda, MSD, Astra Zeneca, BMS, Menarini, Novartis, GSK, Solvay, Roche, Servier and Schering Plough	None

DRAFT FOR CONSULTATION

Group Member	Personal specific pecuniary or personal family interest	Personal non-specific pecuniary interest	Non-personal specific pecuniary interest	Non-personal non-specific pecuniary interest	Personal non-pecuniary interest
Richard Wray	Occasional lecture (e.g. 17.10.06) for pharmaceutical companies; educational/non-promotional	None	None	None	None